舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁与焦虑共病的研究

Study on Senile Comorbidity of Depression and Anxiety Treated with Shugan Jieyu Capsules and Escitalopram

目的探讨舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁焦虑共病的疗效与安全性。方法 2012年10月-2014年5月精神科门诊和住院患者68例,随机分成对照组与治疗组。治疗组用舒肝解郁胶囊联合艾司西酞普兰治疗,对照组单用艾司西酞普兰,两组疗程均为8周。采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评定疗效。采用药物不良反应评定量表(TESS)评定治疗中不良反应的安全性。结果两组患者HAMD和HAMA的评分在治疗后均明显降低,与本组治疗前比较,8周后评分明显下降,差异具有统计学意义(P<0.05)。两组HAMD和HAMA在第1、2周末评分,差异无统计学意义(P>0.05);第4、8周后评分均下降显著,差异具有统计学意义(P<0.01)。两组患者治疗8周末对照组总有效率为67.6%,治疗组为85.2%,治疗组总有效率明显优于对照组(P<0.05)。两组TESS评分在治疗后1、2、4及8周末比较,差异均无统计学意义(P>0.05)。结论舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁与焦虑共病疗效好,不良反应少,安全性好。

Objective To explore the efficacy and safety in the treatment of senile comorbidity of depression and anxiety with shugan jieyu capsules and escitalopram. Methods Sixty eight cases of senile co-morbidity of depression and anxiety were collected from October 2012 to May 2014 and randomized into a control group and a treatment group. In the treatment group,the combined medication with shugan jieyu cap-sules and escitalopram was used. In the control group,escitalopram was used. The duration of treatment was 8 weeK in either group. HAMD and HAMA were adopted for the efficacy assessment. TESS was applied to the safety assessment in terms of adverse reactions in the treatment. Results After treatment,HAMD and HAMA scores were all reduced apparently in the two groups. The scores were all reduced apparently in 8 weeKs of treatment as compared with those before treatment in the same group,indicating the significant difference（P﹤ 0. 05）. The differences were not significant in the scores of HAMD and HAMA in the 1 and 2 weeKs of treatment of the two groups（P ﹥ 0. 05）. The scores were reduced significantly in the 4 and 8 weeKs of treat-ment,indicating the significant difference（P ﹤ 0. 01）. The total effective rate was 67. 6% in the control group and was 85. 2% in the treatment group in the 8 weeKs of treatment in the two groups. The total effective rate in the treatment group was superior apparently to the control group（P ﹤ 0. 05）. TESS scores were not differ-ent significantly in 1,2,4 and 8 weeKs of treatment in the two groups separately（P ﹥ 0. 05）. Conclusion The combined medication with shugan jieyu capsules and escitalopram achieves the satisfactory efficacy on senile comorbidity of depression and anxiety,with less adverse reactions and good safety.